RemI for Post-Bariatric Surgery Weight Regain
Temple University · with Rush University · NCT06292936
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–70 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 200
- US sites recruiting
- 2
- Study start
- April 15, 2024
- Record last updated
- April 3, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to test the effectiveness of remotely-delivered interventions (utilizing acceptance-based behavioral treatment skills (ABTi)) amongst bariatric surgery populations who are experiencing weight regain postoperatively (> 5% from their lowest postoperative weight and after postoperative Month 6). Investigators aim to evaluate ABTi's efficacy for reversing weight regain and its effect on targeted weight control behaviors and weight-related comorbidities by comparing participants randomly assigned ABTi (n = 100) to those assigned to a Control group that also receives brief phone calls but that focus on reiterating instruction on the dietary and behavioral changes required of surgery and initially taught preoperatively (C, n = 100).
The main research aims are
- To compare changes in body weight over 12 months in 200 bariatric patients who have regained > 5% of their weight and are randomly assigned to ABTi or Control.
- To compare changes in eating behaviors (i.e., caloric intake, frequency of maladaptive eating behaviors), physical activity, and weight-related comorbidities (i.e., biomarkers of diabetes, hypertension) over 12 months in the two groups.
- Exploratory - To test ABTi's theoretical mechanisms of action, including a) effects of theory-based active ingredients (i.e., acceptance, defusion, values clarity, mindfulness) on weight outcomes and b) changes in impact of internal states (i.e., hunger, cravings) on eating behavior.
Being studied: Acceptance-Based Behavioral Intervention
Conditions: Obesity; Bariatric Surgery Candidate
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Men and women
- Ages 18-70 years old
- Weight regain of at least 5% from lowest postoperative weight
- Body mass index (BMI) 25 or above
- Underwent gastric bypass or sleeve gastrectomy within 6 to 48 months prior to enrollment
- Ability to give consent
- Ability to speak, write, and understand English
Exclusion Criteria
- Long-term treatment with oral steroids
- Current use of weight loss medication (OTC or prescription)
- Current pregnancy, plan to become pregnant within 12 months, lactation within the past 6 months
- Psychiatric hospitalization in the past 6 months
- Documented or self-reported psychiatric diagnosis that would interfere with adherence to the study protocol or acute suicidality
- Self-report of alcohol or substance abuse within the past 12 months
- Current, self-reported use of tobacco products
- Weight loss > 10 lbs in the past 3 month
- History of more than one bariatric procedure
- Inability to walk at least one city block without assistance
Recruiting US locations
Rush University
Chicago, IL 60612
Site contact: Lauren Bradley, PhD · 312-942-2714 · lauren_e_bradley@rush.edu
Temple University
Philadelphia, PA 19104
Site contact: David B Sarwer, PhD · 215-707-8632 · dsarwer@temple.edu
Study contacts (from the official record)
- David B Sarwer, PhD · 215-707-8632 · dsarwer@temple.edu
- Sarah R Fischbach, MPH · 215-707-8633 · sarah.fischbach@temple.edu
Similar studies in Illinois
All weight loss studies in Illinois →- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Skokie, IL + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Chicago, IL + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Alveus Therapeutics, Inc.
- Location
- Champaign, IL + 19 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass
Boston Scientific Corporation
- Location
- Chicago, IL + 8 other US sites
- Eligibility basics
- Ages 18+